And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, not surprisingly, is quite modest. We plan to enjoy a library book, listen to new mixes of favorite old music, hang with a short person or two, and promenade with the official mascot. And what about you? This remains a fine time to enjoy the great outdoors. You could go online to ensure your mail-in ballot is on its way. Or you could reach out to someone feeling isolated these days. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

U.S. researchers have begun two clinical trials examining the use of blood thinners to help Covid-19 patients avoid clotting that has led to strokes, heart attacks, and organ failure, Bloomberg News writes. In one study, the National Institutes of Health will look at the use of apixaban in people who have not been hospitalized. Apixaban is sold under the brand name Eliquis by Bristol Myer Squibb (BMY) and Pfizer (PFE), with the first generic versions approved last year. The other trial will study the use of heparin in patients who are hospitalized.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy